The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ISAL 2019 | Triplebody development process
Georg Fey, PhD, of the University of Erlangen Nuremberg, Erlangen and Nuremberg, Germany, discusses the development of the lead triplebody candidate and the manufacturing process. Prof. Fey highlights the catch 42 the team are facing in moving this agent into trials, due to the external effector cells that the therapy utilizes. This interview took place at the International Symposium on Acute Leukemias (ISAL) 2019, held in Munich, Germany.
